DP303c + irinotecan liposomes

DP303c + irinotecan liposomes is a **combination drug** under investigation for the treatment of **HER2-expressing gastric adenocarcinoma and gastroesophageal junction adenocarcinoma** in patients who have progressed after one or two prior lines of systemic therapy. **DP303c** is an antibody-drug conjugate (ADC) consisting of an anti-HER2 monoclonal antibody linked to the microtubule inhibitor monomethyl auristatin E (MMAE) via an enzyme-specific linker, enabling targeted cytotoxicity to HER2-positive tumor cells. **Irinotecan liposomes** is a pegylated liposomal formulation of irinotecan, a topoisomerase I inhibitor, providing prolonged circulation and enhanced tumor accumulation through the enhanced permeability and retention (EPR) effect and improved pharmacokinetics compared to conventional irinotecan. The combination leverages the targeted action of the ADC and the DNA-damaging effect of irinotecan to potentially improve efficacy in this cancer subtype[3][7].